

WYDUR Board Meeting Minutes
Thursday, July 20, 2006
Laramie, Wyoming
11 a.m. – 3 p.m.

Members present: Steve Brown, Michael Carpenter, Becky Drnas, Bill Harrison, Kurt Hopfensperger, Richard Johnson, Scott Johnston, Bill Keenan, Kevin Robinett, Dean Winsch, Antoinette Brown, Aimee Lewis

By teleconference: Deb Devereaux, Kendra Grande

Guests: Bert Jones (GlaxoSmithKline), John Stockton (Genentech), Richard Leslie (Wyoming Epilepsy Association), Terri Craig (Pfizer), Ben Thompson (Pharmacy Student), Jeff Jenkins (Merck), Rick Realsen (Merck), Shane Hartson (Eli Lilly and Company), Lisa Dickerson (Eli Lilly and Company), Jessica McMahan (Pharmacy Student)

Dr. Harrison called the meeting to order at 11:05.

Minutes of May 2006

The minutes of the May 25, 2006 meeting were approved as presented.

Department of Health

The new Cyber Access program has been implemented. This program allows prescribers to look at Medicaid client history. The Department has contacted sixteen physicians across the state, so far the response has been good.

Aimee provided information on the Consumer Reports Best Buy Drugs website.

Smart PA is going well. The Office of Pharmacy Services has seen a decline in second PA requests since implementation.

The presentation from APS was cancelled. Dr. Harrison will meet with Dr. Sherard to discuss concerns.

Effective 8/1, stimulants will go through for ninety days.

Old Business

The Board discussed off-label utilization of anticonvulsants. The Board agreed to approve labeled uses for all anticonvulsants. Prior authorization will be required for all off-label uses.

**Proposed Criteria for Use of Antiepileptic Agents
WY-DUR Board 7-20-06**

The following antiepileptic agents would be approved ONLY for the designated indications:

Gabapentin – epilepsy, neuropathic pain

Lamotrigine – epilepsy, bipolar disorder

Levetiracetam – epilepsy

Oxycarbazepine – epilepsy

Pregabalin – epilepsy, neuropathic pain secondary to diabetes with neurologic manifestations, and post herpetic neuralgia

Topiramate – epilepsy and migraine

Zonisamide – epilepsy

In addition, the following criteria will apply:

Pregabalin (Lyrica) – If diagnosis of neuropathic pain associated with diabetic peripheral neuropathy or postherpetic neuralgia, the patient must first fail treatment with gabapentin in the last 1 year.

The Board reviewed provider responses to the Angiotensin II Receptor Blockers (A2RBs). The criteria were changed to reflect provider suggestions and approved as follows.

**Final criteria for use of Angiotensin II Receptor Blockers
WY-DUR Board 7-20-06**

Angiotensin II Receptor Blockers (A2RB): candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan

A2RB combinations: candesartan/hydrochlorothiazide, eprosartan/hydrochlorothiazide, olmesartan/hydrochlorothiazide, telmisartan/hydrochlorothiazide, valsartan/hydrochlorothiazide

- Trial and failure of one ACE inhibitor
- Intolerance, adverse reaction or allergic reaction to one ACE inhibitor

Kendra provided an update on the mental health project. The antipsychotic profiles will be tables until the next meeting. Quetiapine utilization will be reviewed by pharmacy students in the fall.

New Business

None

Other

Richard Leslie from the Wyoming Epilepsy Association asked for more consumer input into Board activities.

There were no open comments.

The Board met to review alert revisions, provider responses and patient profiles. There being no further business the meeting was adjourned at 2:30 p.m.

Respectfully Submitted,

Aimee Lewis, PharmD
WYDUR Manager